Sanofi's Oral Aubagio Jostles For Position In Multiple Sclerosis Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA accepts filing for teriflunomide, but concerns about pregnancy risk in a young patient population and questions about comparative efficacy could limit market potential.